IRIS
ZUCALI, PAOLO ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.258
EU - Europa 1.157
AS - Asia 605
AF - Africa 194
Continente sconosciuto - Info sul continente non disponibili 20
SA - Sud America 16
OC - Oceania 4
Totale 6.254
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.187
FI - Finlandia 318
SG - Singapore 313
IE - Irlanda 277
NG - Nigeria 190
CN - Cina 168
IT - Italia 129
DE - Germania 105
FR - Francia 101
SE - Svezia 77
CA - Canada 71
NL - Olanda 62
TR - Turchia 53
GB - Regno Unito 41
IL - Israele 24
BE - Belgio 14
IN - India 14
EU - Europa 13
IR - Iran 12
BR - Brasile 10
A2 - ???statistics.table.value.countryCode.A2??? 7
ES - Italia 5
AU - Australia 4
CH - Svizzera 4
CL - Cile 4
EG - Egitto 4
ID - Indonesia 4
JP - Giappone 4
RU - Federazione Russa 4
TW - Taiwan 4
UA - Ucraina 4
GR - Grecia 3
HK - Hong Kong 3
BD - Bangladesh 2
CO - Colombia 2
CZ - Repubblica Ceca 2
IQ - Iraq 2
LT - Lituania 2
RO - Romania 2
AT - Austria 1
BG - Bulgaria 1
DK - Danimarca 1
EE - Estonia 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
NO - Norvegia 1
PT - Portogallo 1
VN - Vietnam 1
Totale 6.254
Salva come PNG Salva come JPEG
Città #
Wilmington 915
Chandler 558
San Mateo 378
Helsinki 316
Dublin 277
Ann Arbor 262
Benin City 190
Lawrence 187
Princeton 187
Singapore 187
Leawood 179
Shanghai 151
New York 128
Woodbridge 121
Ashburn 116
Fairfield 100
Paris 100
Boardman 93
Amsterdam 62
Toronto 56
Kocaeli 52
Milan 48
London 32
Phoenix 32
Seattle 28
San Diego 25
Redwood City 24
Norwalk 21
Brussels 14
Los Angeles 14
Monmouth Junction 13
Redmond 11
Santa Clara 10
Pune 9
Andover 7
Winnipeg 7
Ardabil 6
Des Moines 6
Nanjing 6
Abbiategrasso 5
Clearwater 5
Falkenstein 5
Frankfurt am Main 5
Houston 5
Montichiari 5
São Paulo 5
Apo 4
Bologna 4
Jakarta 4
Prineville 4
Fiumicino 3
Ottawa 3
Rome 3
Sacramento 3
San Marcello Pistoiese 3
Taipei 3
Al Ma`adi 2
Athens 2
Brno 2
Buffalo 2
Cambridge 2
Catania 2
Collegeville 2
Dhaka 2
Espoo 2
Gunzenhausen 2
Indianapolis 2
Jacksonville 2
Kwun Hang 2
Logroño 2
Medellín 2
Moscow 2
Munich 2
Niscemi 2
Parma 2
Pioltello 2
Sovico 2
Springfield 2
Sydney 2
Vancouver 2
Addison 1
Adliswil 1
Al Manzalah 1
Albano Laziale 1
Ankara 1
Aprilia 1
Aracaju 1
Basel 1
Beijing 1
Bethesda 1
Borås 1
Cairo 1
Chennai 1
Clinton 1
Crema 1
Curitiba 1
Dalsjoefors 1
Eden Prairie 1
Everett 1
Feira de Santana 1
Totale 5.065
Salva come PNG Salva come JPEG
Nome #
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer 79
Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study) 72
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 68
721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study 65
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib 56
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 56
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma 56
Gene methylation in pleural mesothelioma : Correlations with clinico-pathological features and patient’s follow-up 55
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 55
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 55
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 55
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 54
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 54
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 54
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? 54
New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma 53
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 53
Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen 53
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 53
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 52
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 52
Digital analysis of intratumoural heterogeneity reveals higher leucocytic infiltrate in VETC (Vessels Encapsulating Tumour Clusters) areas 52
Assessment of tumor response in malignant pleural mesothelioma 51
Baseline Radiomic CT Features Differentiate Mediastinal Masses As Thymic Neoplasms Or Lymphomas 51
Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas 51
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial 51
Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: Analysis of its use in 427 cancer patients 50
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors 50
Advances in the biology of malignant pleural mesothelioma 50
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 50
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer 49
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 49
Reproducibility of the WHO classification of thymomas: practical implications 49
Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation 47
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 46
Biology and management of malignant pleural mesothelioma 46
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors 46
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma 45
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 45
Anti-angiogenic therapies for malignant pleural mesothelioma 45
Expression and mutational status of c-kit in thymic epithelial tumors 44
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 44
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 44
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [F-18]fluorodeoxyglucose 43
Baseline and early change of systemic inflammation index (bSII and ΔSII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study 43
Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study 43
Positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM): Prediction of response to chemotheraphy by quantitative assessment of standard uptake value (SUV) 42
NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study 41
Management of germ cell tumors during the outbreak of the novel coronavirus disease‐19 pandemic: a survey of international expertise centers 41
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 41
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma 40
Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines 40
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients 39
Malignant pleural mesothelioma (MPM) evaluation with C-11-methionine PET/CT before and after talc pleurodesis 39
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 39
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 38
Imaging biomarkers in primary brain tumours 38
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin 37
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study 36
Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy and medical treatment in 60 patients 36
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab as first-line therapy in malignant pleural mesothelioma 36
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas 36
Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor alpha, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma 36
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 36
"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma 36
Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study 36
Safety and activity of Combined AVElumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study 36
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations 35
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 35
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors 35
The neural phenotype in invasive urothelial carcinoma patients: Alternative score detection and prognostic implication 35
Positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM): Evaluation of response to chemotherapy by quantitative assessment of standardized uptake value (SUV) 34
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 34
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 34
Future developments in the management of malignant pleural mesothelioma 34
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 34
Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S) 34
SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial 34
Uncommon manifestations of common malignancies - Case 1. Soft-tissue metastases from malignant pleural mesothelioma 33
Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice. 33
The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer 33
Survival Outcomes in Malignant Pleural Mesothelioma Patients Fit for Surgery According to Type of Procedure and Completeness of Resection 33
Can sentinel node biopsy avoid axillary dissection in clinically node-negative breast cancer patients? 33
Advances in drug treatments for mesothelioma 32
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. 32
Thymoma and thymic carcinomas. 32
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS 32
Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients 32
Retrospective analysis of an alternative immuno-score in clinical management of patients with pT2 urothelial carcinoma 32
Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM) 31
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors 31
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 31
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 31
[Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?] 31
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study 31
Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: a new category of patients for clinical studies? 30
Timing of response evaluation with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant pleural mesothelioma (MPM): "Early'' versus "late'' assessment 30
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma 30
Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC) 30
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2 30
Totale 4.258
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.786
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.786
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202040 0 0 0 0 0 0 0 0 0 0 0 40
2020/20211.931 18 16 23 15 13 659 286 119 358 215 7 202
2021/20221.014 49 29 28 185 15 6 37 128 100 112 290 35
2022/20231.975 408 65 217 169 131 127 6 127 322 224 161 18
2023/20241.345 117 142 244 40 30 183 84 78 27 28 140 232
2024/2025195 20 70 23 38 44 0 0 0 0 0 0 0
Totale 6.500